التفاصيل البيبلوغرافية
| العنوان: |
Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries. |
| المؤلفون: |
Chiattone, Carlos, Gomez-Almaguer, David, Pavlovsky, Carolina, Tuna-Aguilar, Elena J., Basquiera, Ana L., Palmer, Luis, de Farias, Danielle Leao Cordeiro, da Silva Araujo, Sergio Schusterschitz, Galvez-Cardenas, Kenny Mauricio, Gomez Diaz, Alvaro, Lin, Jennifer H., Chen, Yen-wen, Machnicki, Gerardo, Mahler, Michelle, Parisi, Lori, Barreyro, Paula |
| المصدر: |
Hematology; Dec2020, Vol. 25 Issue 1, p366-371, 6p |
| مصطلحات موضوعية: |
CHRONIC lymphocytic leukemia, OLDER patients, THERAPEUTIC complications, CHRONIC leukemia, LOG-rank test, STATISTICAL hypothesis testing |
| مستخلص: |
To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America. This chart review study (NCT02559583; 2008–2015)evaluated time to progression (TTP) and overall survival (OS) outcomes among patients with CLL who initiate done (n = 261) to two (n = 96) lines of therapy (LOT) since diagnosis. Differences in TTP and OS were assessed by Kaplan-Meier analysis, with a log-rank test for statistical significance. Association between therapeutic regimen and risk for disease progression or death was estimated using Cox proportional hazard regression. The most commonly prescribed therapies in both LOTs were chlorambucil-, followed by fludarabine- and cyclophosphamide (C)/CHOP-based therapies. Chlorambucil- and C/CHOP-based therapies were largely prescribed to elderly patients (≥65 years) while fludarabine-based therapy was predominantly used by younger patients (≤65 years). In LOT1, relative to chlorambucil-administered patients, those prescribed fludarabine-based therapies had lower risk of disease progression (hazard ratio [HR] and 95% confidence interval [CI] 0.32 [0.19–0.54]), whereas C/CHOP-prescribed patients had higher risk (HR 95%CI 1.88 [1.17–3.04]). Similar results were observed in LOT2. There was no difference in OS between treatments in both LOTs. Novel therapies such as kinase inhibitors were rarely prescribed in LOT1 or LOT2in Latin America. The greater TTP observed forfludarabine-based therapies could be attributed to the fact that fludarabine-based therapies are predominantly administered to young and healthy patients. Chlorambucil-based therapy, which has limited benefits, is frequently prescribed in Latin America. Prescribing novel agents for fludarabine-based therapy-ineligible patients with CLL is the need of the hour. Trial registration: ClinicalTrials.gov identifier: NCT02559583. [ABSTRACT FROM AUTHOR] |
|
Copyright of Hematology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
